Chimerix’s proprietary lipid conjugate technology has enabled the discovery of two novel, orally available nucleotide analogs: brincidofovir (CMX001), our lead clinical-stage molecule, and CMX157. Both of these molecules are chemically modified versions of antiviral drugs that had important limitations. Cidofovir was only available in intravenous form and was associated with significant renal toxicity, whereas tenofovir was also associated with important renal and bone side effects. Through the application of our lipid conjugate technology, we have been able to transform the profile of both of these molecules. We welcome opportunities to explore collaborations that could result in the discovery of other new orally available molecules.
Chimerix continuously seeks to access external innovation where it can help speed the development of potential life-saving medicines to patients while creating long-term value. With a focus on extending patients’ lives who are suffering from life-threatening diseases, we have specific interest in partnering for clinical-stage assets in virology and oncology where we can
leverage our substantial expertise. For more information about our interests and how we might work together to advance innovation, please contact Mike Andriole, Chief Business Officer, at firstname.lastname@example.org
Key benefits of collaborating with Chimerix include:
- Strong culture of innovation
- Extensive clinical development and regulatory experience
- Commercial group with proven track record of successful product launches
- Creativity in constructing partnerships
- Commitment to professional alliance management
- Public company infrastructure
In 2011, Chimerix initiated a partnership with the U.S. Biomedical Advanced Research and Development Authority (BARDA) to develop brincidofovir (CMX001) as a medical countermeasure to treat smallpox outbreaks due to a bioterror event or accidental release. Brincidofovir has received Fast Track designation from the FDA for smallpox, adenovirus and cytomegalovirus.
CMX157 (Tenofovir Exalidex TXL™) is a novel lipid acyclic nucleoside phosphonate that delivers high intracellular concentrations of the active antiviral agent tenofovir diphosphate. TXL is active against hepatitis B virus (HBV) and more than 200-fold more potent in vitro
versus tenofovir against all major HIV subtypes resistant to current therapies. TXL’s novel structure results in decreased circulating levels of tenofovir, lowering systemic exposure and thereby reducing the potential for renal side effects. ContraVir intends to develop TXL as a potential treatment for HBV and HIV. TXL has demonstrated a favorable safety, tolerability and drug distribution profile in a Phase 1 clinical trial in healthy volunteers.
For more information about our interests and how we might work together to advance innovation, please contact Mike Andriole, Chief Business Officer, at email@example.com